Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 7—July 2021
CME ACTIVITY - Research

Non–C. difficile Clostridioides Bacteremia in Intensive Care Patients, France

Guillaume MorelComments to Author , Guillaume Mulier, Etienne Ghrenassia, Moustafa Abdel Nabey, Yacine Tandjaoui, Achille Kouatchet, Laura Platon, Frédéric Pène, Anne-Sophie Moreau, Amelie Seguin, Damien Contou, Romain Sonneville, David Rousset, Muriel Picard, Guillaume Dumas, Djamel Mokart, Bruno Megarbane, Guillaume Voiriot, Isabelle Oddou, Elie Azoulay, Lucie Biard, and Lara Zafrani
Author affiliations: Hautepierre Hospital—University Medical Center, Strasbourg, France (G. Morel); Hospital Saint Louis, APHP, Paris, France (G. Morel, G. Mulier, E. Ghrenassia, M.A. Nabey, E. Azoulay, L. Biard, L. Zafrani); Hospital Avicenne, Bobigny, France (Y. Tandjaoui); Teaching Hospital, Angers, France (A. Kouatchet); Lapeyronie University Hospital, Montpellier, France (L. Platon); Hospital Cochin, APHP, Paris (F. Pène); Salengro Hospital, Lille, France (A.-S. Moreau); University Hospital, Nantes, France (A. Seguin); Victor Dupouy Hospital, Argenteuil, France (D. Contou); Hospital Bichat, APHP, Paris (R. Sonneville); University Teaching Hospital, Toulouse, France (D. Rousset),; Institut Universitaire du Cancer—Oncopole, Toulouse (M. Picard); Hospital Saint Antoine, APHP, Paris (G. Dumas); Paoli-Calmettes Institute, Marseille, France (D. Mokart); Hospital Lariboisiere, APHP, Paris (B. Megarbane); Hospital Tenon, APHP, Paris (G. Voiriot); University Medical Center, Strasbourg (I. Oddou); INSERM U976, Paris (L. Zafrani)

Cite This Article

Introduction

CME Logo

Medscape CME ACTIVITY

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at https://www.medscape.org/journal/eid; and (4) view/print certificate.

Release date: Jun 18, 2021; Expiration date: Jun 18, 2022
Learning Objectives

Upon completion of this activity, participants will be able to:

  • Assess the background of patients with Clostridioides bacteremia (CB) in the current study

  • Distinguish clinical features of severe CB in the current study

  • Assess the microbiology of CB in the current study

  • Identify risk factors for mortality due to CB in the current study

CME Editor

Dana C. Dolan, BS, Copyeditor, Emerging Infectious Diseases. Disclosure: Dana C. Dolan, BS, has disclosed the following relevant financial relationships: employed by a commercial interest (spouse): Micro C Imaging.

CME Author

Charles P. Vega, MD, Health Sciences Clinical Professor of Family Medicine, University of California, Irvine School of Medicine, Irvine, California. Disclosure: Charles P. Vega, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for GlaxoSmithKline.

Authors

Disclosures: Guillaume Morel, MD; Guillaume Mulier, MSc; Etienne Ghrenassia, MD; Moustafa Abdel-Nabey, MD; Yacine Tandjaoui, MD; Achille Kouatchet, MD;Laura Platon, MD; Anne-Sophie Moreau, MD; Amelie Seguin, MD; Damien Contou, MD; Romain Sonneville, MD, PhD; David Rousset, MD; Muriel Picard, MD; Guillaume Dumas, MD, PhD; Djamel Mokart, MD, PhD; Bruno Megarbane, MD, PhD; Guillaume Voiriot, MD; Isabelle Oddou, MD; and Lucie Biard, MD, PhD, have disclosed no relevant financial relationships. Frédéric Pène, MD, PhD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Gilead Sciences, Inc.; received grants for clinical research from Alexion Pharmaceuticals, Inc. Elie Azoulay, MD, PhD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Gilead Sciences, Inc.; served as a speaker or a member of a speakers bureau for Astellas Pharma, Inc.; Gilead Sciences, Inc.; Merck Sharp & Dohme; received grants for clinical research from Ablynx NV; Alexion Pharmaceuticals, Inc.; Baxter; Fisher and Payckle, Gilead Sciences, Inc.; Jazz Pharmaceuticals, Inc. Lara Zafrani, MD, PhD, has disclosed the following relevant financial relationships: received grants for clinical research from: Jazz Pharmaceuticals, Inc.

Top

Abstract

Usually responsible for soft tissue infections, Clostridioides species can also cause bacteremia, life-threatening infections often requiring intensive care unit (ICU) admission. We conducted a multicenter retrospective study to investigate Clostridioides bacteremia in ICUs to describe the clinical and biologic characteristics and outcomes in critically ill patients. We identified 135 patients with Clostridioides bacteremia, which occurred almost exclusively (96%) in patients with underlying conditions. Septic shock and digestive symptoms were the hallmarks of Clostridioides bacteremia in the ICU. We identified 16 different species of Clostridioides, among which C. perfringens accounted for 31% of cases. Despite the high sensitivity of Clostridioides to common antimicrobial drugs, mortality rates were high: 52% for ICU patients and 71% overall at 3 months. In multivariate analysis, the most important factor associated with increased risk for death was the presence of hemolysis. Clostridioides bacteremia often leads to multiple organ failures, which have high mortality rates.

Obligate anaerobic bacteremia is a rare event, accounting for ≈0.1%–10% of positive blood cultures; Clostridioides spp. bacteremia represents 8%–46% of the cases (14). Clostridioides (formerly Clostridium) species are ubiquitous, gram-positive, spore-forming (most species), and toxin-producing bacteria (3). The most well-known toxins, C. perfringens α and θ toxins, induce platelet aggregation, diffuse formation of thrombi, cell lysis, and gas gangrene (5). Anaerobic bacteria are not only found in the soil or rotting vegetation but also are commensal constituents of the human microbiome, especially in the gastrointestinal tract or genital organs of women (3,6). Humans are usually infected by direct entry of the bacteria through a wound (C. tetani, C. perfringens) or by contaminated food (C. botulae). However, contamination of a wound by spores is not sufficient to generate the infection because Clostridioides spp. need hypoxic and acidic conditions to proliferate. Conditions such as vascular trauma, atherosclerosis, or malignancies may induce tissue hypoxia. Moreover, the liberation of both α and θ toxin, which induce the formation of occlusive thrombi, may increase tissue hypoxia, sometimes leading to gas gangrene formation (3,79).

Thus, Clostridioides infections are especially known to cause myonecrosis with rapid extension and gas gangrene formation, which, if not treated rapidly, may be fatal. This outcome has largely been described in the context of war wounds, trauma, and surgery (1012). Although C. perfringens is mostly involved in gas gangrene, other Clostridioides subspecies can also be responsible for such infections (13).

Clostridioides bacteria can also cause primary bacteremia, with or without gas gangrene (2,6). Clostridioides bacteremia are usually fulminant and life-threatening infections. Data focusing on Clostridioides bacteremia rely mainly on case reports (1416), case series on selected populations (17,18), or larger epidemiologic series that contain microbiological data but few clinical descriptions (2,19,20). Although Clostridioides bacteremia often leads to sudden and massive organ failure requiring transfer to a hospital intensive care unit (ICU), no study has focused on Clostridioides bacteremia in the ICU. Therefore, we conducted a multicenter retrospective study of case-patients who were positive for all Clostridioides species except C. difficile to investigate Clostridioides bacteremia in the ICU; we described the clinical spectrum of critically ill patients, ICU admission conditions, microbiological characteristics, and outcomes. We aimed to identify risk factors associated with mortality.

Methods

Ethics

This study was approved by an Institutional Review Board (Comité d’Ethique de la Société de Réanimation de Langue Française no. CE-SRLF 18–38) in accordance with the French regulation on noninterventional studies, which waived the need for signed informed consent for patients included in this database. No data allowing identification of the patients included in the study were recorded. The study was conducted in accordance with the Declaration of Helsinki principles.

Study Population

We retrospectively recorded cases of Clostridioides bacteremia in the period July 2003–December 2018 in 15 ICUs in France. Patients were identified by review of ICU medical records and hospital microbiological databases; we selected only cases with >1 positive blood culture for all Clostridioides species except C. difficile. Blood samples had been collected with specific anaerobic blood culture bottles and incubated in automated systems, in accordance with routine practice (21). Anaerobes were identified using the API System (bioMérieux, https://www.biomerieux.com) until 2010; as of 2010, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry methods were used in most of the centers to identify anaerobic bacteria (3,22). Antimicrobial susceptibility test results of Clostridioides species, evaluated by diffusion methods according to guidelines of the Comité de l’Antibiogramme de la Société Française de Microbiologie, were also collected for our study.

We reviewed ICU medical records of selected patients for age, sex, underlying diseases, clinical and biologic symptoms at ICU admission, the need for organ support, antimicrobial drug treatment, and outcome. We recorded Charlson index, simplified acute physiology score (SAPS2), and sequential organ failure assessment (SOFA) scores as previously defined (2325). We defined septic shock according to the Sepsis-3 consensus definition (26) and hemolysis as low hemoglobin level associated with other hemolysis parameters, such as an increase of lactate dehydrogenase (LDH) or unconjugated bilirubin and reduced haptoglobin levels.

Statistical Analysis

We described categorical variables as counts and percentages and quantitative variables as median and interquartile range. We estimated mortality rate at 28 days and 90 days after the date of bacteremia, as a binary variable, and examined factors associated with overall survival as a time-to-event endpoint. We defined overall survival as the time between the date of Clostridioides bacteremia and the date of death or last follow-up, whichever occurred first. We performed survival analysis using a Cox regression model, estimating hazard ratios (HR) and 95% CIs. We checked the proportional hazards (PH) assumption and the log-linearity assumptions for the models; if the PH assumption was not valid, we used time-dependent coefficient for time-varying effect over time; we used a step function, with time-intervals defined based on the Schoenfeld’s residuals. Factors which were associated to OS with a p<0.1 in univariate analysis were candidates for a multivariate adjusted model. We selected the adjusted model using a backward stepwise procedure, based on the Akaike criterion. All tests were 2-sided; p<0.05 was considered significant. We performed analyses by using the R statistical platform version 3.6.1 (https://www.r-project.org).

Results

Clinical and Biologic Manifestations

In total, 135 patients with Clostridioides bacteremia were identified in 15 ICUs in France during the study period (Table 1); 60% (n = 81) of the patients were men. Median age at diagnosis was 64 years. Most (96%) patients had >1 underlying medical condition; among patients >65 years of age, diabetes mellitus, neoplasms, and chronic obstruction pulmonary disease (COPD) were the most frequent. Thirty-four (26%) patients had an underlying solid tumor from digestive (n = 14, 41%), gynecological (n = 7, 21%), and pancreatic or biliary (n = 4, 12%) origins. Three patients (9%) had urinary tract tumors, 2 (6%) neuroendocrine tumors, 1 (3%) an Ewing tumor, 1 (3%) oral cancer, and 1 (3%) testicular cancer. In all, 94% of tumors were active at the time of the bacteremia. Nineteen (15%) patients had also received diagnoses of hematological malignancies (7 lymphoma, 4 acute lymphoblastic leukemia, 4 myelodysplastic syndrome, 3 acute myeloid leukemia, and 1 myeloproliferative disorder); 3 of those patients had undergone bone marrow transplantation. Thirty-eight patients (28%) had been treated with immunosuppressive agents. In addition, 13 (10%) patients had experienced recent surgery or trauma, and these situations were associated with a better outcome in univariate analysis (Appendix Figure 1). However, this difference was not significant in multivariate analysis (HR 0.41, 95% CI 0.13–1.32; p = 0.13) (Figure 1).

Clostridioides bacteremia manifested with septic shock at ICU admission in 115 patients (85%), and 26 (19%) patients experienced a cardiac arrest in the ICU (Table 2). Indeed, Clostridioides bacteremia causes severe illness, as assessed by high SAPS2 and SOFA scores, high lactate levels, and substantial need for organ supports during an ICU stay. Of note, digestive symptoms were the main symptoms associated with Clostridioides bacteremia (62% of patients), whereas myonecrosis represented only 16% of ICU admissions. Acute hemolysis, a distinctive biologic signature of Clostridioides bacteremia, was present in 22 (17%) cases (Appendix Table 1). Median hemoglobin level was significantly lower in the hemolysis group (4.9, IQR 3.6–7.0) compared with the rate in patients without hemolysis (10.9, IQR 9.3–12.6; p<0.001). Multiple organ failure, experienced as hepatic cytolysis, acute kidney injury and thrombocytopenia (Table 2), was also common. Of note, aspartate aminotransferase levels were higher than alanine aminotransferase levels, which is commonly found in case of hemolysis. Twenty-seven patients (28%) had <4 × 109 leukocytes/L; 23 (85%) of those had an underlying solid tumor or a hematological malignancy.

Documentation of Infectious Species

In total, 16 different Clostridioides species were identified by blood cultures, including C. perfringens in one third of the patients (Table 3; Figure 2). In univariate analysis, documented C. perfringens infection was not associated with a worse outcome than other Clostridioides species (HR 0.78, CI 95% 0.49–1.23; p = 0.285) (Appendix Figure 2). Blood cultures were mainly performed by peripheral venipuncture (58%), followed by central venous catheter puncture (23%) and arterial catheter puncture (17%). One blood culture revealed Clostridioides bacteremia in 87% of cases. Of note, 49 cases of Clostridioides bacteremia were polymicrobial bacteremia, yielding the presence of >1 type of bacteria in blood cultures, balanced between gram-negative, gram-positive, and other anaerobic bacteria. Nine patients had both gram-negative and gram-positive bacteria cultures. Hematogenous spread with gas-forming abscess was one particular complication, found in 9 patients and leading to death in 5 in the ICU (Figure 3, panels A–C). As suggested by clinical symptoms, cases of bacteremia were mostly from the gastrointestinal tract (74%), followed by myonecrosis (16%) (Figure 3, panels D–E). In total, 110 (91%) of the patients were treated with antimicrobial drugs in the ICU, and 64 (47%) patients underwent surgery that was mostly gastrointestinal surgery (67% of surgery interventions).

Most strains of Clostridioides were sensitive to β-lactam drugs. Clostridioides species were sensitive to clindamycin in 69% of the cases. Two species (C. tertium and C. septicum) were resistant to metronidazole. We did not find any association between specific antimicrobial agents used to treat Clostridioides bacteremia and mortality (HR 1.01, 95% CI 0.57–1.77; p = 0.977) (Appendix Table 2).

Outcomes and Mortality Risk Factors

Although Clostridioides spp. were for the most part efficiently treated by common antimicrobial drugs, Clostridioides bacteremia remained very aggressive and life-threatening; the overall mortality rate at 6 months was 71%. Of 135 patients, 84 died; 70 (52%) of all patients died in the ICU. The 28-day mortality rate was 55% (95% CI 45%–64%), and the 90-day mortality rate was 71% (95% CI 60%–79%). The rapid need for hospitalization after the occurrence of the first symptoms (median days 0, IQR 0–1) highlighted the aggressiveness of Clostridioides bacteremia; direct ICU transfer was necessary in most cases (median time between hospitalization and ICU transfer 0 days, IQR 0–2). Median length of stay in ICU was 2 days for patients who did not survive (IQR 1.25–5.75) and 11 days for survivors (IQR 5–23).

In multivariate analysis for overall survival, factors associated with increased risk for death were increasing age (in 5-year increments) (HR 1.19, 95% CI 1.08–1.31; p<0.001), increasing SOFA score (per point) (HR 1.12, 95% CI 1.06–1.19; p<0.001), and presence of hemolysis (HR 2.39, 95% CI 1.31–4.38; p = 0.005). On the other hand, male sex was associated with a reduced risk for death (HR 0.56, 95% CI 0.34–0.91; p = 0.02) (Figure 2).

Discussion

In our study, we found that Clostridioides bacteremia is an aggressive and rapidly life-threatening infection, occurring mainly in patients with underlying conditions. Septic shock with digestive symptoms is the usual manifestation. Despite rapid transfer to the ICU, large use of organ support, and active antimicrobial treatment, Clostridioides bacteremia remains highly lethal; 52% of ICU patients died. Massive intravascular hemolysis, associated with fatal complications, should alert clinicians to the possibility of sepsis.

Data on Clostridioides bacteremia consist mainly of case reports (1416,27) or case series that include a small number of patients (17,2830). Larger publications focusing on anaerobic bacteremia do not provide details on patients’ characteristics and outcomes (2,19). Furthermore, we could find no previous publications on Clostridioides bacteremia in ICU patients, even though anaerobic bacteremia is frequent in this population (2,31). Our study provides a thorough description of the clinical and biologic characteristics as well as the outcomes of this serious condition.

Our results are consistent with earlier reports; most Clostridioides bacteremia cases occur in patients >65 years of age, and prevalence is higher in men (17,29,31). Diseases such as diabetes, chronic kidney disease, heart failure, and COPD, which maintain a baseline degree of organ ischemia and cause chronic organ failure, can lead to Clostridioides proliferation and consequently to bacteremia (1,19,29,31). Cancer patients or patients with hematological malignancies are also at high risk (18,32). Chemotherapy-induced cytopenia may result in neutropenic enterocolitis (33); this impairment of the natural digestive barrier favors the development of Clostridioides bacteremia. Digestive symptoms that have been described as hallmarks of this condition (1,17,29) were frequently associated with Clostridioides bacteremia in the ICU. Of note, although Clostridioides bacteremia is mostly from digestive origins, myonecrosis was identified as the origin of the bacteremia in 16% of the cases in our study, which is consistent with previous reports (17,18,29,31).

Among Clostridioides species, C. perfringens was more often identified as the source of bacteremia, as previously published (1,19,34). Fifteen other Clostridioides species have been identified; distribution is similar to the one described by Leal et al. (19). In this study, we chose to exclude C. difficile infections because this pathogen is mainly responsible for healthcare-associated digestive infections. C. difficile can still present as extradigestive infections; however, few cases of bacteremia have been reported (35,36).

Data on incidence of anaerobic and Clostridioides bacteremia are conflicting. Some authors report an increasing incidence of anaerobic bacteremia since the 1990s, whereas other report decreasing trends (2,6,20,37). The incidence of anaerobic bacteremia depend on patients’ age and underlying conditions (especially cancer or cardiovascular illness), and antibiotic selection pressure driven by antimicrobial drug use and environmental conditions. In addition, as suggested by Morris et al. (38), blood cultures for anaerobic bacteria may be influenced by patients’ background and clinical symptoms. Indeed, in a recent study evaluating anaerobic bacteremia, 39.7% of the positive blood cultures were considered to be bloodstream infections; the remaining 60.3% were attributed to contaminants (39). The evolution of microbiologic techniques, including growing use of automated techniques and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, might have also influenced the increasing isolation of anaerobic bacteremia. Although we cannot rule out that some infections may have been overestimated, the severity of clinical presentations in our cohort suggests that these cases resulted from true bloodstream infections.

Of note, Clostridioides bacteremia can present either as a single microbial bacteremia or as a polymicrobial bacteremia (2,28,30,31). Enterobacteriaceae were the most commonly associated bacteria, followed by Staphylococcus species. Cultures for multiple microbes were positive for Clostridioides spp. in 18 patients. Comparable results were also found by Fujita et al. (17). Clostridioides species are largely susceptible to common antimicrobial drugs, except for clindamycin; susceptibility for clindamycin has been reported as reduced by 73%–96% (1,3,5,19,31). High susceptibility to penicillin should alert clinicians to rapidly initiate treatment in identified cases of Clostridioides bacteremia. Because 94% of the patients in our study received adequate antimicrobial drugs within 24 hours of ICU admission, we were not able to find any statistical association between early initiation of drugs and death. However, in a recent study published by Stabler et al. (34), adequate empiric antimicrobial therapy was associated with a better outcome. This result was also highlighted previously by Zahar et al. (18).

Mortality rates for Clostridioides bacteremia reported in the literature were 15%–48% (1719,2831), which is lower than the mortality rates reported in our study. However, we focused on critically ill patients. Indeed, Yang (17) and Fujita (31) revealed that patients who developed shock and required transfer to the ICU had worse outcomes than other patients. In those studies, shock was statistically associated with increased deaths. The prognosis for Clostridioides bacteremia patients is also related to underlying conditions that predispose to Clostridioides bacteremia and possibilities of therapeutic interventions in addition to prompt and appropriate antimicrobial drugs. As demonstrated by Rechner et al. (1), patients who required medical intervention to treat Clostridioides bacteremia had lower survival rates than patients who were managed by surgery. Conversely, the presence of massive intravascular hemolysis is a marker of extreme severity, despite appropriate management (16,40). Hemolysis is induced by Clostridioides toxin A (29), which hydrolyzes phospholipids in erythrocyte membranes, causing spherocytosis and subsequent intravascular hemolysis. Present in 17% of patients in our cohort, hemolysis is associated with a dramatic increase in mortality rate and remains a strong prognostic factor identified in our study. Finally, Clostridioides bacteremia in the ICU is associated with a higher mortality rate than that for classic septic shock in the ICU (41,42), which makes Clostridioides bacteremia a particularly difficult infection to deal with in the ICU.

The first limitation of our study is its retrospective nature and the inherently associated bias, such as missing data and unidentified confounding factors that may have been overlooked in the data collection. However, because of the rarity of Clostridioides bacteremia, prospective studies would hardly be feasible. Second, there are no standardized ICU admission policies for these patients, and patient recruitment patterns may have influenced the findings. Given the rapidity of the onset of symptoms and the severity of illness, rapid ICU management was the rule in the participating centers. However, we could not exclude that some patients, because of their advanced age or underlying conditions, were considered too sick for admission to the ICU and may have been denied intensive care.

In conclusion, Clostridioides bacteremia is an aggressive infection that often leads to failure of multiple organs, requiring prompt intensive care management. Particular attention should be paid to patients who have underlying conditions and are experiencing hemolysis. Early administration of antimicrobial agents active against Clostridioides bacteremia is essential, considering that most Clostridioides species are sensitive to β-lactams drugs. Even with prompt and appropriate management, however, Clostridioides bacteremia is associated with a high mortality rate in the ICU.

Top

References

  1. Rechner  PM, Agger  WA, Mruz  K, Cogbill  TH. Clinical features of clostridial bacteremia: a review from a rural area. Clin Infect Dis. 2001;33:34953. DOIPubMed
  2. Gajdács  M, Ábrók  M, Lázár  A, Terhes  G, Urbán  E. Anaerobic blood culture positivity at a University Hospital in Hungary: A 5-year comparative retrospective study. Anaerobe. 2020;63:102200. DOIPubMed
  3. Gajdács  M, Spengler  G, Urbán  E. Identification and antimicrobial susceptibility testing of anaerobic bacteria: Rubik’s cube of clinical microbiology? Antibiotics (Basel). 2017;6:25. DOIPubMed
  4. Blairon  L, De Gheldre  Y, Delaere  B, Sonet  A, Bosly  A, Glupczynski  Y. A 62-month retrospective epidemiological survey of anaerobic bacteraemia in a university hospital. Clin Microbiol Infect. 2006;12:52732. DOIPubMed
  5. Stevens  DL, Aldape  MJ, Bryant  AE. Life-threatening clostridial infections. Anaerobe. 2012;18:2549. DOIPubMed
  6. Gajdács  M, Urbán  E. Relevance of anaerobic bacteremia in adult patients: A never-ending story? Eur J Microbiol Immunol (Bp). 2020;10:6475. DOIPubMed
  7. Bryant  AE, Chen  RY, Nagata  Y, Wang  Y, Lee  CH, Finegold  S, et al. Clostridial gas gangrene. I. Cellular and molecular mechanisms of microvascular dysfunction induced by exotoxins of Clostridium perfringens. J Infect Dis. 2000;182:799807. DOIPubMed
  8. Bryant  AE, Chen  RY, Nagata  Y, Wang  Y, Lee  CH, Finegold  S, et al. Clostridial gas gangrene. II. Phospholipase C-induced activation of platelet gpIIbIIIa mediates vascular occlusion and myonecrosis in Clostridium perfringens gas gangrene. J Infect Dis. 2000;182:80815. DOIPubMed
  9. Ohyama  K, Fujimoto  M, Nakagomi  Y, Ohta  M, Yamori  T, Kato  K. Effect of cyproterone acetate on active and inactive renin secretion in patients with precocious puberty and genetic short stature. Horm Res. 1991;36:2169. DOIPubMed
  10. Takazawa  T, Ohta  J, Horiuchi  T, Hinohara  H, Kunimoto  F, Saito  S. A case of acute onset postoperative gas gangrene caused by Clostridium perfringens. BMC Res Notes. 2016;9:385. DOIPubMed
  11. North  JP. Clostridial wound infections and gas gangrene; arterial damage as a modifying factor. Surgery. 1947;21:36472.PubMed
  12. MacLennan  JD. The histotoxic clostridial infections of man. Bacteriol Rev. 1962;26:177276. DOIPubMed
  13. Srivastava  I, Aldape  MJ, Bryant  AE, Stevens  DL. Spontaneous C. septicum gas gangrene: A literature review. Anaerobe. 2017;48:16571. DOIPubMed
  14. Shen  A, Ologun  GO, Behm  R. Fulminant hepatic failure and fatal cerebral edema following Clostridium perfringens bacteremia: case report and review of literature. Cureus. 2017;9:e1714. DOIPubMed
  15. Wazir  M, Jain  AG, Nadeem  M, Ur Rahman  A, Everett  G. Clostridium tertium bacteremia in a non-neutropenic patient with liver cirrhosis. Cureus. 2019;11:e4432. DOIPubMed
  16. Simon  TG, Bradley  J, Jones  A, Carino  G. Massive intravascular hemolysis from Clostridium perfringens septicemia: a review. J Intensive Care Med. 2014;29:32733. DOIPubMed
  17. Fujita  H, Nishimura  S, Kurosawa  S, Akiya  I, Nakamura-Uchiyama  F, Ohnishi  K. Clinical and epidemiological features of Clostridium perfringens bacteremia: a review of 18 cases over 8 year-period in a tertiary care center in metropolitan Tokyo area in Japan. Intern Med. 2010;49:24337. DOIPubMed
  18. Zahar  JR, Farhat  H, Chachaty  E, Meshaka  P, Antoun  S, Nitenberg  G. Incidence and clinical significance of anaerobic bacteraemia in cancer patients: a 6-year retrospective study. Clin Microbiol Infect. 2005;11:7249. DOIPubMed
  19. Leal  J, Gregson  DB, Ross  T, Church  DL, Laupland  KB. Epidemiology of Clostridium species bacteremia in Calgary, Canada, 2000-2006. J Infect. 2008;57:198203. DOIPubMed
  20. De Keukeleire  S, Wybo  I, Naessens  A, Echahidi  F, Van der Beken  M, Vandoorslaer  K, et al. Anaerobic bacteraemia: a 10-year retrospective epidemiological survey. Anaerobe. 2016;39:549. DOIPubMed
  21. Kirn  TJ, Weinstein  MP. Update on blood cultures: how to obtain, process, report, and interpret. Clin Microbiol Infect. 2013;19:51320. DOIPubMed
  22. Lévesque  S, Dufresne  PJ, Soualhine  H, Domingo  MC, Bekal  S, Lefebvre  B, et al. A side by side comparison of Bruker Biotyper and VITEK MS: utility of MALDI-TOF MS technology for microorganism identification in a public health reference laboratory. PLoS One. 2015;10:e0144878. DOIPubMed
  23. Moreno  R, Vincent  JL, Matos  R, Mendonça  A, Cantraine  F, Thijs  L, et al. Working Group on Sepsis-related Problems of the ESICM. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Intensive Care Med. 1999;25:68696. DOIPubMed
  24. Charlson  ME, Pompei  P, Ales  KL, MacKenzie  CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:37383. DOIPubMed
  25. Le Gall  JR, Lemeshow  S, Saulnier  F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:295763. DOIPubMed
  26. Singer  M, Deutschman  CS, Seymour  CW, Shankar-Hari  M, Annane  D, Bauer  M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:80110. DOIPubMed
  27. Fukui  M, Iwai  S, Sakamoto  R, Takahashi  H, Hayashi  T, Kenzaka  T. Clostridium paraputrificum bacteremia in an older patient with no predisposing medical condition. Intern Med. 2017;56:33957. DOIPubMed
  28. Lopez-Fabal  MF, Sanz  N, Ruiz-Bastian  M, Barros  C, Gomez-Garces  JL. Clostridium perfringens bacteremia, an analysis of 28 cases over 10 years in a university hospital of Madrid [in Spanish]. Enferm Infecc Microbiol Clin. 2018;36:2258. DOI
  29. Shindo  Y, Dobashi  Y, Sakai  T, Monma  C, Miyatani  H, Yoshida  Y. Epidemiological and pathobiological profiles of Clostridium perfringens infections: review of consecutive series of 33 cases over a 13-year period. Int J Clin Exp Pathol. 2015;8:56977.PubMed
  30. Shah  M, Bishburg  E, Baran  DA, Chan  T. Epidemiology and outcomes of clostridial bacteremia at a tertiary-care institution. ScientificWorldJournal. 2009;9:1448. DOIPubMed
  31. Yang  CC, Hsu  PC, Chang  HJ, Cheng  CW, Lee  MH. Clinical significance and outcomes of Clostridium perfringens bacteremia—a 10-year experience at a tertiary care hospital. Int J Infect Dis. 2013;17:e95560. DOIPubMed
  32. Lark  RL, McNeil  SA, VanderHyde  K, Noorani  Z, Uberti  J, Chenoweth  C. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis. 2001;33:33843. DOIPubMed
  33. Duceau  B, Picard  M, Pirracchio  R, Wanquet  A, Pène  F, Merceron  S, et al. Neutropenic enterocolitis in critically ill patients: spectrum of the disease and risk of invasive fungal disease. Crit Care Med. 2019;47:66876. DOIPubMed
  34. Stabler  S, Titécat  M, Duployez  C, Wallet  F, Loïez  C, Bortolotti  P, et al. Clinical relevance of Clostridium bacteremia: An 8-year retrospective study. Anaerobe. 2020;63:102202. DOIPubMed
  35. Libby  DB, Bearman  G. Bacteremia due to Clostridium difficile—review of the literature. Int J Infect Dis. 2009;13:e3059. DOIPubMed
  36. Urbán  E, Terhes  G, Gajdács  M. Extraintestinal Clostridioides difficile infections: epidemiology in a university hospital in Hungary and review of the literature. Antibiotics (Basel). 2020;9:16. DOIPubMed
  37. Lassmann  B, Gustafson  DR, Wood  CM, Rosenblatt  JE. Reemergence of anaerobic bacteremia. Clin Infect Dis. 2007;44:895900. DOIPubMed
  38. Morris  AJ, Wilson  ML, Mirrett  S, Reller  LB. Rationale for selective use of anaerobic blood cultures. J Clin Microbiol. 1993;31:21103. DOIPubMed
  39. Lafaurie  M, d’Anglejan  E, Donay  JL, Glotz  D, Sarfati  E, Mimoun  M, et al. Utility of anaerobic bottles for the diagnosis of bloodstream infections. BMC Infect Dis. 2020;20:142. DOIPubMed
  40. Dutton  D, Gavrilova  N. Massive intravascular hemolysis with organ failure due to Clostridium perfringens: evidence of intracytoplasmic C. perfringens. Blood. 2013;122:310. DOIPubMed
  41. Angus  DC, Linde-Zwirble  WT, Lidicker  J, Clermont  G, Carcillo  J, Pinsky  MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:130310. DOIPubMed
  42. Shankar-Hari  M, Phillips  GS, Levy  ML, Seymour  CW, Liu  VX, Deutschman  CS, et al.; Sepsis Definitions Task Force. Developing a new definition and assessing new clinical criteria for septic shock. JAMA. 2016;315:77587. DOIPubMed

Top

Figures
Tables

Top

Follow Up

Earning CME Credit

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to https://www.medscape.org/journal/eid. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers.

You must be a registered user on http://www.medscape.org. If you are not registered on http://www.medscape.org, please click on the “Register” link on the right hand side of the website.

Only one answer is correct for each question. Once you successfully answer all post-test questions, you will be able to view and/or print your certificate. For questions regarding this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@medscape.net. American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please go to https://www.ama-assn.org. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.

Article Title: 
Non–C. difficile Clostridioides Bacteremia in Intensive Care Patients, France
CME Questions
  • Which of the following statements regarding the background of patients admitted to the intensive care unit (ICU) with Clostridioides bacteremia (CB) in the current study is most accurate?

    • Approximately half of patients with CB had no underlying comorbidities

    • >40% of patients with CB had cancer

    • >60% of patients had recent surgery or trauma

    • Septic shock at the time of admission was rare

  • Which of the following statements regarding the clinical presentation of patients with CB in the current study is most accurate?

    • Digestive symptoms were the most common presenting symptoms

    • Myonecrosis was present at admission in most patients

    • Most patients had evidence of acute hemolysis

    • Most patients had evidence of acute leukopenia

  • Which of the following statements regarding the microbiology of CB among patients in the current study was most accurate?

    • C. perfringens was isolated from > 30% of patients

    • < 10% of cases were polymicrobial

    • The rate of Clostridioides resistance to β-lactam antibiotics exceeded 50%

    • Patients treated with clindamycin experienced lower mortality rates compared with other antibiotics

  • All of the following factors were associated with a higher risk for death due to CB in the current study EXCEPT:

    • Older age

    • Higher Sequential Organ Failure Assessment (SOFA) score

    • Male sex

    • The presence of hemolysis

Top

Cite This Article

DOI: 10.3201/eid2707.203471

Original Publication Date: June 04, 2021

Related Links

Table of Contents – Volume 27, Number 7—July 2021

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Guillaume Morel, Medical Intensive Care Unit, Hospital Hautepierre—Hôpitaux Universitaires de Strasbourg, 1 Avenue Molière, BP 83049, 67098 Strasbourg CEDEX, France

Send To

10000 character(s) remaining.

Top

Page created: May 27, 2021
Page updated: June 18, 2021
Page reviewed: June 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external